{"name":"Astellas Pharma Europe Ltd.","slug":"astellas-pharma-europe-ltd","ticker":"","exchange":"","domain":"astellaspharmaeurope.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":600000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Evrenzo","genericName":"ROXADUSTAT","slug":"roxadustat","revenue":600000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":600000000,"percentOfTotal":100,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Evrenzo","genericName":"ROXADUSTAT","slug":"roxadustat","indication":"Anemia in chronic kidney disease","status":"marketed","revenue":600000000}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"immunology","drugs":[{"name":"ASP1707 single dose fed","genericName":"ASP1707 single dose fed","slug":"asp1707-single-dose-fed","indication":"Other","status":"phase_1"},{"name":"ASP1128","genericName":"ASP1128","slug":"asp1128","indication":"Other","status":"phase_2"},{"name":"ASP1707 multiple dose of dose levels 1-2","genericName":"ASP1707 multiple dose of dose levels 1-2","slug":"asp1707-multiple-dose-of-dose-levels-1-2","indication":"Other","status":"phase_1"},{"name":"ASP1707 multiple dose of dose levels 1-4","genericName":"ASP1707 multiple dose of dose levels 1-4","slug":"asp1707-multiple-dose-of-dose-levels-1-4","indication":"Other","status":"phase_1"},{"name":"ASP1707 single dose fasted","genericName":"ASP1707 single dose fasted","slug":"asp1707-single-dose-fasted","indication":"Other","status":"phase_1"},{"name":"ASP1707 single dose of dose levels 1 -7","genericName":"ASP1707 single dose of dose levels 1 -7","slug":"asp1707-single-dose-of-dose-levels-1-7","indication":"Other","status":"phase_1"},{"name":"ASP3652","genericName":"ASP3652","slug":"asp3652","indication":"Complement-mediated inflammatory disorders (Phase 2 development)","status":"phase_2"},{"name":"ASP6282","genericName":"ASP6282","slug":"asp6282","indication":"Other","status":"phase_1"},{"name":"ASP6294 Intravenous","genericName":"ASP6294 Intravenous","slug":"asp6294-intravenous","indication":"Other","status":"phase_1"},{"name":"ASP6294 Subcutaneous","genericName":"ASP6294 Subcutaneous","slug":"asp6294-subcutaneous","indication":"Other","status":"phase_1"},{"name":"ASP6858","genericName":"ASP6858","slug":"asp6858","indication":"Other","status":"phase_1"},{"name":"ASP7713","genericName":"ASP7713","slug":"asp7713","indication":"Other","status":"phase_1"},{"name":"Betmiga®","genericName":"Betmiga®","slug":"betmiga","indication":"Prevention of kidney stones","status":"phase_2"},{"name":"Placebo to match mirabegron","genericName":"Placebo to match mirabegron","slug":"placebo-to-match-mirabegron","indication":"Placebo control for mirabegron trials in overactive bladder","status":"phase_3"},{"name":"Placebo to match solifenacin succinate","genericName":"Placebo to match solifenacin succinate","slug":"placebo-to-match-solifenacin-succinate","indication":"Placebo control for solifenacin succinate trials in overactive bladder","status":"phase_3"},{"name":"bismuth tripotassium dicitrate","genericName":"bismuth tripotassium dicitrate","slug":"bismuth-tripotassium-dicitrate","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"infectious","drugs":[{"name":"Vancomycin capsules","genericName":"Vancomycin capsules","slug":"vancomycin-capsules","indication":"Treatment of infections caused by susceptible Gram-positive bacteria, including MRSA","status":"phase_3"},{"name":"Vancomycin oral liquid","genericName":"Vancomycin oral liquid","slug":"vancomycin-oral-liquid","indication":"Treatment of Clostridioides difficile infection","status":"phase_3"},{"name":"Fidaxomicin oral suspension","genericName":"Fidaxomicin oral suspension","slug":"fidaxomicin-oral-suspension","indication":"Clostridioides difficile infection (CDI), including initial and recurrent episodes","status":"phase_3"},{"name":"Fidaxomicin tablets","genericName":"Fidaxomicin tablets","slug":"fidaxomicin-tablets","indication":"Clostridioides difficile infection (CDI), including initial episode and recurrent infection","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"ASP8232","genericName":"ASP8232","slug":"asp8232","indication":"Treatment of autoimmune diseases","status":"phase_2"},{"name":"FK506E","genericName":"FK506E","slug":"fk506e","indication":"Prevention of organ rejection in transplant recipients","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"ASP8477","genericName":"ASP8477","slug":"asp8477","indication":"Relapsed or refractory non-Hodgkin lymphoma","status":"phase_2"},{"name":"Eligard","genericName":"Eligard","slug":"eligard","indication":"Advanced Prostatic Carcinoma","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"respiratory","drugs":[{"name":"ASP6294","genericName":"ASP6294","slug":"asp6294","indication":"Relapsing multiple sclerosis","status":"phase_2"},{"name":"ASP7962","genericName":"ASP7962","slug":"asp7962","indication":"Relapsing multiple sclerosis","status":"phase_2"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"Locobase® REPAIR","genericName":"Locobase® REPAIR","slug":"locobase-repair","indication":"Dry skin and skin barrier dysfunction","status":"marketed"}]}],"pipeline":[{"name":"Evrenzo","genericName":"ROXADUSTAT","slug":"roxadustat","phase":"marketed","mechanism":"Thyroid hormone receptor beta","indications":["Anemia in chronic kidney disease","Refractory anemia (clinical)"],"catalyst":""},{"name":"ASP1707 single dose fed","genericName":"ASP1707 single dose fed","slug":"asp1707-single-dose-fed","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP8232","genericName":"ASP8232","slug":"asp8232","phase":"phase_2","mechanism":"ASP8232 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Treatment of autoimmune diseases"],"catalyst":""},{"name":"ASP8477","genericName":"ASP8477","slug":"asp8477","phase":"phase_2","mechanism":"ASP8477 is a small molecule that targets the CDK9 protein.","indications":["Relapsed or refractory non-Hodgkin lymphoma"],"catalyst":""},{"name":"FK506E","genericName":"FK506E","slug":"fk506e","phase":"phase_3","mechanism":"FK506E is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, preventing IL-2 production and T-cell proliferation.","indications":["Prevention of organ rejection in transplant recipients","Autoimmune and inflammatory conditions (phase 3 development)"],"catalyst":""},{"name":"Vancomycin capsules","genericName":"Vancomycin capsules","slug":"vancomycin-capsules","phase":"phase_3","mechanism":"Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.","indications":["Treatment of infections caused by susceptible Gram-positive bacteria, including MRSA"],"catalyst":""},{"name":"Vancomycin oral liquid","genericName":"Vancomycin oral liquid","slug":"vancomycin-oral-liquid","phase":"phase_3","mechanism":"Vancomycin oral liquid inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of cell wall precursors.","indications":["Treatment of Clostridioides difficile infection","Treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections"],"catalyst":""},{"name":"ASP1128","genericName":"ASP1128","slug":"asp1128","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1707 multiple dose of dose levels 1-2","genericName":"ASP1707 multiple dose of dose levels 1-2","slug":"asp1707-multiple-dose-of-dose-levels-1-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1707 multiple dose of dose levels 1-4","genericName":"ASP1707 multiple dose of dose levels 1-4","slug":"asp1707-multiple-dose-of-dose-levels-1-4","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1707 single dose fasted","genericName":"ASP1707 single dose fasted","slug":"asp1707-single-dose-fasted","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1707 single dose of dose levels 1 -7","genericName":"ASP1707 single dose of dose levels 1 -7","slug":"asp1707-single-dose-of-dose-levels-1-7","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP3652","genericName":"ASP3652","slug":"asp3652","phase":"phase_2","mechanism":"ASP3652 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.","indications":["Complement-mediated inflammatory disorders (Phase 2 development)"],"catalyst":""},{"name":"ASP6282","genericName":"ASP6282","slug":"asp6282","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP6294","genericName":"ASP6294","slug":"asp6294","phase":"phase_2","mechanism":"ASP6294 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Relapsing multiple sclerosis"],"catalyst":""},{"name":"ASP6294 Intravenous","genericName":"ASP6294 Intravenous","slug":"asp6294-intravenous","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP6294 Subcutaneous","genericName":"ASP6294 Subcutaneous","slug":"asp6294-subcutaneous","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP6858","genericName":"ASP6858","slug":"asp6858","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP7713","genericName":"ASP7713","slug":"asp7713","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP7962","genericName":"ASP7962","slug":"asp7962","phase":"phase_2","mechanism":"ASP7962 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Relapsing multiple sclerosis"],"catalyst":""},{"name":"Betmiga®","genericName":"Betmiga®","slug":"betmiga","phase":"phase_2","mechanism":"Betmiba works by increasing the levels of magnesium in the urine, which helps to prevent kidney stones.","indications":["Prevention of kidney stones"],"catalyst":""},{"name":"Eligard","genericName":"Eligard","slug":"eligard","phase":"marketed","mechanism":"Gonadotropin-releasing hormone receptor, Gonadotropin-releasing hormone receptor","indications":["Advanced Prostatic Carcinoma","Anemia due to Bleeding Uterine Leiomyoma","Endometriosis","Precocious puberty"],"catalyst":""},{"name":"Fidaxomicin oral suspension","genericName":"Fidaxomicin oral suspension","slug":"fidaxomicin-oral-suspension","phase":"phase_3","mechanism":"Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, selectively killing Clostridioides difficile while minimizing effects on normal gut flora.","indications":["Clostridioides difficile infection (CDI), including initial and recurrent episodes"],"catalyst":""},{"name":"Fidaxomicin tablets","genericName":"Fidaxomicin tablets","slug":"fidaxomicin-tablets","phase":"phase_3","mechanism":"Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, selectively killing Clostridioides difficile while minimizing effects on normal gut flora.","indications":["Clostridioides difficile infection (CDI), including initial episode and recurrent infection"],"catalyst":""},{"name":"Locobase® REPAIR","genericName":"Locobase® REPAIR","slug":"locobase-repair","phase":"marketed","mechanism":"Locobase® REPAIR is an emollient and skin barrier repair product that restores skin hydration and protects damaged skin through occlusive and humectant ingredients.","indications":["Dry skin and skin barrier dysfunction","Symptomatic relief of xerosis and atopic dermatitis-prone skin"],"catalyst":""},{"name":"Placebo to match mirabegron","genericName":"Placebo to match mirabegron","slug":"placebo-to-match-mirabegron","phase":"phase_3","mechanism":"This is an inert placebo formulation designed to match the physical and sensory characteristics of mirabegron for blinded clinical trial purposes.","indications":["Placebo control for mirabegron trials in overactive bladder"],"catalyst":""},{"name":"Placebo to match solifenacin succinate","genericName":"Placebo to match solifenacin succinate","slug":"placebo-to-match-solifenacin-succinate","phase":"phase_3","mechanism":"This is a placebo formulation designed to match the appearance and administration of solifenacin succinate for blinded clinical trial purposes.","indications":["Placebo control for solifenacin succinate trials in overactive bladder"],"catalyst":""},{"name":"bismuth tripotassium dicitrate","genericName":"bismuth tripotassium dicitrate","slug":"bismuth-tripotassium-dicitrate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQbVB4M0JrSVVaZGNxSkc2NnZoeUpFcDJsN2tzTnBOdUtRZ3JqaC05Z1J4c3JYeUZoZzIwMXgyU3c1Zm02NjNWbGdvQzdnSlhxak43R3BmeDY2RUtpcjhpSHRucUZiTUU0VFc1elZJdDRhYVIyS1ZZZFVfbnRLMzN5SXpEWDM5SWF0WGl1VE9SeU1WYzRQSTFBZHpIWndUbmp2SUVwWE1KOUVhYnB6VE8wSUlR?oc=5","date":"2026-03-19","type":"pipeline","source":"thepost.co.za","summary":"Court ruling secures affordable prostate cancer treatment in South Africa - thepost.co.za","headline":"Court ruling secures affordable prostate cancer treatment in South Africa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQNWQxWUxXeG9kOFVWYnpNNlRUU0JPdHl3Z3M5N0xNMFJhSVVUcEg1cmM4WElRaXhsVE9aZDRrUHgtZzJZWmVNT1NrdmJzazdTVXUzdERKTnVSV004cG15RVY2dmMxUm1DWWdhTkpfMnNtYUxZMjV4S2lWM0pvbFIySjRwMkZrdGd1QWFNS3k3VDk0cVpQY0ZyYjY4dkJSN2ppVWpnUEUwdWJyYmJMYnEtMnBOSzMyWjU0T3c?oc=5","date":"2026-03-16","type":"pipeline","source":"AD HOC NEWS","summary":"Astellas Pharma Inc Stock (ISIN: JP3942400007) Faces Headwinds Amid Oncology Pipeline Setbacks - AD HOC NEWS","headline":"Astellas Pharma Inc Stock (ISIN: JP3942400007) Faces Headwinds Amid Oncology Pipeline Setbacks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOMmlZTEdzdXp0ckFnTTYydVU0ZUNINDJUd2d5cjhtOTBWSUhFZ2tJQWEzRWhXY0lKcnV4el9LOXZzNWlOb21DNE1Fc0ZhcW5pdmRnSGhPaEEtNjBNNVRrS0lITDkzOE9KaDQyR3F4QWN6UHpCekp6MXB3TUt5OENHck9FU2tLUlJGbFFfbzBDT0t5ajB5UWZFT3Vab3F1dzFIcWlFRnBocHNQeWNGOGozRS0tWmVzNnptQUE?oc=5","date":"2026-03-13","type":"pipeline","source":"AD HOC NEWS","summary":"Astellas Pharma Inc Stock (ISIN: JP3942400007) Faces Headwinds Amid Oncology Pipeline Setbacks - AD HOC NEWS","headline":"Astellas Pharma Inc Stock (ISIN: JP3942400007) Faces Headwinds Amid Oncology Pipeline Setbacks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQMlZHcW4tcHgxRmlqRlhHYmpmWmVvRDZTWnN0aGVTcDFoNTF1S1pieUZWd1VNYWhNYU1ibXZ5WTJqOGVBaWp5YXM4UlNHNFpWeUJrR203ZXpTZ1hoQUgwUno1RGUzOTJMYWNTVm0yNVZ1NmhTWXBIVnNzcnpXdTJjQjV1WUdTa0dtTzdpOWFVYTc4VFZhQjNIcmdIb3ctNUxac0Nr?oc=5","date":"2025-08-21","type":"pipeline","source":"BioPharm International","summary":"Astellas and Pfizer Bladder Cancer Therapy Recommended by UK’s NICE - BioPharm International","headline":"Astellas and Pfizer Bladder Cancer Therapy Recommended by UK’s NICE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQcWduZXZCZzc0NkltdExuTWI1SmdZNkVZUjJaU1dHTzQzcWE4Y1ZIcDRWcFR5Rk9RSUlJZm9LdktRanNYU0JGWEcxOWlocTl4VVpBaXpiRzdOb1phNXN4cjc3NDJsWDZ1R3htUjhuRnJLMzB3ZVhKazNvS2ZyMXFLQXRzZXlMaWYxWkFadlhEUjRLT2N1ajNIWXIxYVdUdVVXbjE2bHpIdw?oc=5","date":"2025-08-20","type":"pipeline","source":"Life Sciences Intellectual Property Review","summary":"Astellas win strengthens blockbuster drug's European position - Life Sciences Intellectual Property Review","headline":"Astellas win strengthens blockbuster drug's European position","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNRnlIVGdXdUFlUWNQR2NBVTl3VUJMVUJOTW10emJla1d2MVhXVUFqVEp2UXNOdzZnVTZmVm04RjJfNldZSEtVa1ZibUVObldfVzcxR2p4dF9nR2NqZVMxdTd0MmUtZGxrSnpvZ0tkRHFlazhEMlVycGNlMHF1N2ZqZkE5Y1NCRFdULUN0SW1nR29HdHBjZUVrMW9SY2hrbmJvSzB6WEhHQVM2UlBxX0Rxb0dZb0FIVkxN?oc=5","date":"2024-10-09","type":"deal","source":"European Biotechnology Magazine","summary":"AviadoBio Ltd inks US$2.2bn gene therapy deal with Astellas Pharma Inc - European Biotechnology Magazine","headline":"AviadoBio Ltd inks US$2.2bn gene therapy deal with Astellas Pharma Inc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQbG1RMzlYb0hTU0g1c2NGckNha2VaZldpRnE2UFJPNlZSQllhdFozaUM4MXJaaEJ0MkZuN3V6Q0pLbnFLMkFCUDlqZ2pTVkxzcHY3ejRhLUp5UmViR2xkQWVFaGVpZ3E1U2twQnRISVBOV0tHZFBJdFhJem1PY0dQR3MxUm14WEVWb0FqRl9MY0tjNjB0NDhxMWpwTU9aN0pzbUo0QWVoM3RkSExzWHNQaEgwdlliLTdmZGNpQzhaU1M0Z085cHc?oc=5","date":"2023-02-05","type":"pipeline","source":"PR Newswire","summary":"Astellas Announces Change of President and CEO and Management Structure - PR Newswire","headline":"Astellas Announces Change of President and CEO and Management Structure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNSjY5WjFrMHZ3NmNTX0g0MTlTQTl0ZVZKWU02RHE3dmdQa1I0SkxPM3BfYUtFYmQ1cDdjWlNjblgzUTh1NFR4cHp5Y0hyMTI5MVozcFFwY2tmXzZEQ3RiY0FZa2tzTnYteFB1MEY5eWoxWkdILUEzcmJmTG0yWjUtaWNuOUlCQ0ZLSVdjMEVCVEs5LUpCZVdtdWtTbU5ac2Q3VUQxNl9rRVhEdUlYOF93S3FqaUVtQ21SV1hETk9pVmdaRmc?oc=5","date":"2022-04-11","type":"pipeline","source":"Pharmaceutical Technology","summary":"Exclusive: How big is the gender pay gap in the pharma industry in Britain? - Pharmaceutical Technology","headline":"Exclusive: How big is the gender pay gap in the pharma industry in Britain?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPRGd5ZUZBME9QQUVLZ2NSM3ctSm5MMWFLLV9xTUtKTnV5OUNOZmVVbkdjZTN4UWJkZmIwRzYyb09mbzRzbzBTSkJkYlB1UkRyRnByRFRUSUdiZnIwaUkyTHNHZC04Y0FNaFdzbXZ3RWhxZjk0NC1xNm5Pd1pIaXRPdXBfdE1QQkNwMVBHVVV5TGgxOVVDclZMWjNNeTkyTWFDc0JPVGdqR0hsNUxYNEFZaENQSlVKZw?oc=5","date":"2018-07-18","type":"pipeline","source":"Bloomberg.com","summary":"Astellas Is Considering Selling Europe Assets to Raise Cash - Bloomberg.com","headline":"Astellas Is Considering Selling Europe Assets to Raise Cash","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE9kd2F4VEdtTWphdWxKcm1qa1VGTHRnTVl4Qk5jMlNiVk9kSm9YMUZjdm11YzVjb1VrclFnMGlZQzgtUkpoSDFTVzE2U2xhQ0dyOVFxWkpZdEV2X2d0ZkxSNWdLXzJaRE1NSDZGSzluOS1sYzhDOVBv?oc=5","date":"2017-06-26","type":"pipeline","source":"pharmaphorum","summary":"Wayward Astellas comes close to UK industry expulsion - pharmaphorum","headline":"Wayward Astellas comes close to UK industry expulsion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPdFd2eWRHZFdHZWtKUHgyTy1tOWluMnh2Q2FRbk5NWVZLWjhiZEhyOFpMb2lxY1NKV3o0b0tNWnlCdURSaVRrTFFCQzE5UkxJRXhMTmZMSVJpdzVqc0RzU0VYNzI0LU5yYXhTc0ZZaThqcWpVM0Rvd2tjSm1yYUdHOGlpYmRJRG14Nm5CYUVnQjUyYWxkdWpVQU9PVjJIWHdaV3lLMGMtdGVXYm9UejdkdHp4MVQ?oc=5","date":"2017-06-23","type":"pipeline","source":"Fierce Pharma","summary":"Astellas UK narrowly dodges expulsion after more trouble with Britain's pharma cops - Fierce Pharma","headline":"Astellas UK narrowly dodges expulsion after more trouble with Britain's pharma cops","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxONWw5Rjd1RU82WF9Xc0VCN283aFMtTWYtWXQ3RWt5NDJHM3NMZUxxWnBiaVRBQ2RzQnlic0RQUnRpbWVYLWRQcEJtMmZYUHFtNVg5TUNwcENBWXVYX1UxZFVmNENYc09RX2dpXy1Ec3pzMXhQOVVKRzlCd1JiWl9pTWFXTHR0WHJSQlU2ZUlTbG1HZ2JRekgzbkpmbG1xRWV2bXhrQ0JXQzdselpNNnk0?oc=5","date":"2016-07-01","type":"pipeline","source":"Chemistry World","summary":"Lies and deception see Astellas UK suspended by trade body - Chemistry World","headline":"Lies and deception see Astellas UK suspended by trade body","sentiment":"neutral"}],"patents":[],"drugCount":28,"phaseCounts":{"marketed":4,"phase_1":10,"phase_2":7,"phase_3":7},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}